Log in

SIGi001-A-11 Gene-edited iPSC line

Donor information

Gender:Female
Ethnicity:Caucasian

Disease status

Donor

Disease: normal

Disease/phenotype related genetic modifications

Disease: corticobasal degeneration
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms
Type of modification: Isogenic
Gene: MAPT
Chromosome location: 17q21.31
Nucleotide sequence HGSV: NM_016834.4 : c.[ c.727 >T; c.[741+16C>T]+[741+16C>T]]
Target locus modification: Mutated
Description: P301S+IVS10+16 C>T; Regarding homozygosity/heterozygosity-

Disease: Progressive supranuclear palsy
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms
Type of modification: Isogenic
Gene: MAPT
Chromosome location: 17q21.31
Nucleotide sequence HGSV: NM_016834.4 : c.[ c.727 >T; c.[741+16C>T]+[741+16C>T]]
Target locus modification: Mutated
Description: P301S+IVS10+16 C>T; Regarding homozygosity/heterozygosity-

General information

Depositor:Sigma-Aldrich
Cell line name:SIGi001-A-11
Cell line alternative names:iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118
Biosamples ID:SAMEA4451118
hPSCreg name:SIGi001-A-11

Related lines

Derived from: SIGi001-A
All subclones of SIGi001-A: SIGi001-A-1, SIGi001-A-10, SIGi001-A-11, SIGi001-A-12, SIGi001-A-13, SIGi001-A-2, SIGi001-A-3, SIGi001-A-4, SIGi001-A-5, SIGi001-A-6, SIGi001-A-7, SIGi001-A-8, SIGi001-A-9
Timepoint: Confluence
Magnification: x10
Timepoint: Confluence
Magnification: x4
At European Collection of Authenticated Cell Cultures (ECACC)
In stock
Cell Line Information Pack
A Cell Line Information Pack (CLIP) is created to communicate cell line specific information relating to restrictions on use to a user accessing cell lines from EBiSC. A CLIP contains information about a cell line including any specific third party obligations (TPOs) relating to, for example, intellectual property (IP) or the donor consent which affect the use of the cell line.